ID GP42_EBVB9 Reviewed; 223 AA. AC P03205; Q777E6; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 24-JAN-2024, entry version 120. DE RecName: Full=Glycoprotein 42; DE Short=gp42; DE Contains: DE RecName: Full=Soluble gp42; GN ORFNames=BZLF2; OS Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4). OC Viruses; Duplodnaviria; Heunggongvirae; Peploviricota; Herviviricetes; OC Herpesvirales; Orthoherpesviridae; Gammaherpesvirinae; Lymphocryptovirus; OC Lymphocryptovirus humangamma4; Epstein-Barr virus (strain GD1). OX NCBI_TaxID=10377; OH NCBI_TaxID=9606; Homo sapiens (Human). RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=6087149; DOI=10.1038/310207a0; RA Baer R., Bankier A.T., Biggin M.D., Deininger P.L., Farrell P.J., RA Gibson T.J., Hatfull G., Hudson G.S., Satchwell S.C., Seguin C., RA Tuffnell P.S., Barrell B.G.; RT "DNA sequence and expression of the B95-8 Epstein-Barr virus genome."; RL Nature 310:207-211(1984). RN [2] RP GENOME REANNOTATION. RX PubMed=12771413; DOI=10.1099/vir.0.19054-0; RA de Jesus O., Smith P.R., Spender L.C., Elgueta Karstegl C., Niller H.H., RA Huang D., Farrell P.J.; RT "Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter RT for the BART (CST, BARF0) RNAs of EBV."; RL Virology 84:1443-1450(2003). RN [3] RP INTERACTION WITH GP25 AND GP85. RX PubMed=9621012; DOI=10.1128/jvi.72.7.5552-5558.1998; RA Wang X., Kenyon W.J., Li Q., Mullberg J., Hutt-Fletcher L.M.; RT "Epstein-Barr virus uses different complexes of glycoproteins gH and gL to RT infect B lymphocytes and epithelial cells."; RL J. Virol. 72:5552-5558(1998). RN [4] RP INTERACTION WITH HUMAN HLA-DRA, AND FUNCTION. RX PubMed=9151859; DOI=10.1128/jvi.71.6.4657-4662.1997; RA Li Q., Spriggs M.K., Kovats S., Turk S.M., Comeau M.R., Nepom B., RA Hutt-Fletcher L.M.; RT "Epstein-Barr virus uses HLA class II as a cofactor for infection of B RT lymphocytes."; RL J. Virol. 71:4657-4662(1997). RN [5] RP FUNCTION. RX PubMed=12042810; DOI=10.1038/nm0602-594; RA Borza C.M., Hutt-Fletcher L.M.; RT "Alternate replication in B cells and epithelial cells switches tropism of RT Epstein-Barr virus."; RL Nat. Med. 8:594-599(2002). RN [6] RP MUTAGENESIS OF TYR-107; TRP-125; GLU-160; PHE-210 AND ARG-220. RX PubMed=15140992; DOI=10.1128/jvi.78.11.5946-5956.2004; RA Silva A.L., Omerovic J., Jardetzky T.S., Longnecker R.; RT "Mutational analyses of Epstein-Barr virus glycoprotein 42 reveal RT functional domains not involved in receptor binding but required for RT membrane fusion."; RL J. Virol. 78:5946-5956(2004). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=15534216; DOI=10.1073/pnas.0407320101; RA Johannsen E., Luftig M., Chase M.R., Weicksel S., Cahir-McFarland E., RA Illanes D., Sarracino D., Kieff E.; RT "Proteins of purified Epstein-Barr virus."; RL Proc. Natl. Acad. Sci. U.S.A. 101:16286-16291(2004). RN [8] RP FUNCTION, AND SOLUBLE FORM. RX PubMed=15613312; DOI=10.1128/jvi.79.2.841-852.2005; RA Ressing M.E., van Leeuwen D., Verreck F.A., Keating S., Gomez R., RA Franken K.L., Ottenhoff T.H., Spriggs M., Schumacher T.N., RA Hutt-Fletcher L.M., Rowe M., Wiertz E.J.; RT "Epstein-Barr virus gp42 is posttranslationally modified to produce soluble RT gp42 that mediates HLA class II immune evasion."; RL J. Virol. 79:841-852(2005). RN [9] RP INTERACTION WITH GP25 AND GP85. RX PubMed=17581996; DOI=10.1128/jvi.00575-07; RA Kirschner A.N., Lowrey A.S., Longnecker R., Jardetzky T.S.; RT "Binding-site interactions between Epstein-Barr virus fusion proteins gp42 RT and gH/gL reveal a peptide that inhibits both epithelial and B-cell RT membrane fusion."; RL J. Virol. 81:9216-9229(2007). RN [10] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 86-221, AND INTERACTION WITH RP HUMAN HLA-DRA AND HLA-DRB1. RX PubMed=11864610; DOI=10.1016/s1097-2765(02)00465-3; RA Mullen M.M., Haan K.M., Longnecker R., Jardetzky T.S.; RT "Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II RT receptor HLA-DR1."; RL Mol. Cell 9:375-385(2002). CC -!- FUNCTION: Plays a role in virion attachment to host B-lymphocytes, CC through binding to leukocyte antigen (HLA) class II and subsequently CC participates in fusion of the virion with host membranes. May act as a CC tropism switch that directs fusion with B-lymphocytes and inhibits CC fusion with epithelial cells. Additionally, hampers T-cell recognition CC via HLA class II molecules through steric hindrance of T-cell receptor- CC class II-peptide interaction. {ECO:0000269|PubMed:12042810, CC ECO:0000269|PubMed:15613312, ECO:0000269|PubMed:9151859}. CC -!- FUNCTION: Soluble gp42 inhibits HLA class II-restricted antigen CC presentation to T-cells through binding to immature and mature HLA CC class II complexes. {ECO:0000269|PubMed:15613312}. CC -!- SUBUNIT: Forms a complex with gp25 and gp85 via its N-terminus; this CC complex is used for invasion of B-lymphocytes. Interacts with human CC HLA-DRA and HLA-DRB1. {ECO:0000269|PubMed:11864610, CC ECO:0000269|PubMed:17581996, ECO:0000269|PubMed:9151859, CC ECO:0000269|PubMed:9621012}. CC -!- SUBCELLULAR LOCATION: Virion membrane {ECO:0000269|PubMed:15534216}. CC Host membrane {ECO:0000305}; Single-pass membrane protein CC {ECO:0000255}. Note=virions synthesized in B-lymphocytes contain a CC lower amount of gp42 due to sequestration by cellular HLA class II CC protein, whereas virions made from epithelial cells has a higher amount CC of gp42. {ECO:0000305}. CC -!- DOMAIN: The C-lectin type domain is essential for virion-induced CC membrane fusion. CC -!- SIMILARITY: Belongs to the epstein barr virus gp42 family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; V01555; CAA24860.1; -; Genomic_DNA. DR EMBL; AJ507799; CAD53422.1; -; Genomic_DNA. DR PIR; F43042; QQBE26. DR RefSeq; YP_401672.1; NC_007605.1. DR PDB; 1KG0; X-ray; 2.65 A; C=86-221. DR PDB; 3FD4; X-ray; 2.40 A; A/B=33-223. DR PDB; 5W0K; X-ray; 3.10 A; X/Y=47-81. DR PDBsum; 1KG0; -. DR PDBsum; 3FD4; -. DR PDBsum; 5W0K; -. DR SMR; P03205; -. DR BioGRID; 971787; 1. DR IntAct; P03205; 1. DR MINT; P03205; -. DR TCDB; 1.G.21.1.1; the epstein barr virus (human herpes virus 4) gp42 (gp42) family. DR DNASU; 3783745; -. DR GeneID; 3783745; -. DR KEGG; vg:3783745; -. DR SIGNOR; P03205; -. DR EvolutionaryTrace; P03205; -. DR Proteomes; UP000153037; Segment. DR GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-KW. DR GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR Gene3D; 3.10.100.10; Mannose-Binding Protein A, subunit A; 1. DR InterPro; IPR016186; C-type_lectin-like/link_sf. DR InterPro; IPR016187; CTDL_fold. DR SUPFAM; SSF56436; C-type lectin-like; 1. PE 1: Evidence at protein level; KW 3D-structure; Disulfide bond; Host membrane; Host-virus interaction; KW Lectin; Membrane; Reference proteome; Transmembrane; Transmembrane helix; KW Virion. FT CHAIN 1..223 FT /note="Glycoprotein 42" FT /id="PRO_0000116279" FT CHAIN 34..223 FT /note="Soluble gp42" FT /id="PRO_0000433226" FT TOPO_DOM 1..8 FT /note="Intravirion" FT /evidence="ECO:0000255" FT TRANSMEM 9..29 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 30..223 FT /note="Virion surface" FT /evidence="ECO:0000255" FT DOMAIN 111..217 FT /note="C-type lectin" FT SITE 33..34 FT /note="Potential cleavage" FT /evidence="ECO:0000305" FT DISULFID 99..138 FT DISULFID 102..115 FT DISULFID 128..214 FT DISULFID 132..216 FT DISULFID 192..208 FT MUTAGEN 107 FT /note="Y->A: Loss of HLA class II binding and fusion FT competence." FT /evidence="ECO:0000269|PubMed:15140992" FT MUTAGEN 125 FT /note="W->G: Loss of HLA class II binding and fusion FT competence." FT /evidence="ECO:0000269|PubMed:15140992" FT MUTAGEN 160 FT /note="E->A: Loss of HLA class II binding and fusion FT competence." FT /evidence="ECO:0000269|PubMed:15140992" FT MUTAGEN 210 FT /note="F->A: Binds to HLA class II but unable to mediate FT fusion." FT /evidence="ECO:0000269|PubMed:15140992" FT MUTAGEN 220 FT /note="R->A: Loss of HLA class II binding and fusion FT competence." FT /evidence="ECO:0000269|PubMed:15140992" FT TURN 66..70 FT /evidence="ECO:0007829|PDB:5W0K" FT TURN 104..106 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 108..111 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 114..118 FT /evidence="ECO:0007829|PDB:3FD4" FT HELIX 127..135 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 139..141 FT /evidence="ECO:0007829|PDB:3FD4" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:3FD4" FT HELIX 149..153 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 174..176 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 179..182 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 187..191 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 193..198 FT /evidence="ECO:0007829|PDB:3FD4" FT STRAND 214..219 FT /evidence="ECO:0007829|PDB:3FD4" SQ SEQUENCE 223 AA; 25257 MW; F87541F6CEC26D74 CRC64; MVSFKQVRVP LFTAIALVIV LLLAYFLPPR VRGGGRVAAA AITWVPKPNV EVWPVDPPPP VNFNKTAEQE YGDKEVKLPH WTPTLHTFQV PQNYTKANCT YCNTREYTFS YKGCCFYFTK KKHTWNGCFQ ACAELYPCTY FYGPTPDILP VVTRNLNAIE SLWVGVYRVG EGNWTSLDGG TFKVYQIFGS HCTYVSKFST VPVSHHECSF LKPCLCVSQR SNS //